Ibogaine trial

Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show: Cash, cash equivalents and short-term investments for $227.5 million, a 6-month $46.5 million operating activities disbursement considering the $273.1...

On Tuesday, Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company’s non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder. The...